Opdivo reported ~60% growth in revenues to just over $1.1 billion in 1Q17, as compared to $704 million in 1Q16.
Bristol-Myers Squibb’s (BMY) top line rose 12% to ~$4.93 billion in 1Q17, driven by an operational growth of 13% in revenues.
Bristol-Myers Squibb’s top line rose 12% to ~$4.9 billion in 1Q17, driven by an operational growth of 13% in revenues.
In 1Q17, WellCare Health Plans’ (WCG) Medicare Health Plans business reported revenues close to $1.1 billion, which represents year-over-year growth of ~12.4%.
WellCare Health Plans has updated its earnings per share guidance from the previously estimated range of $6.00–$6.25 to the new range of $6.55–$6.80.
In 1Q17, WellCare Health Plans (WCG) reported revenues of ~$3.9 billion, which totals year-over-year growth of around 11.7%.
In 1Q17, WellCare Health Plans’ (WCG) Medicaid business reported revenues close to $2.6 billion, which equals year-over-year growth of ~11.8%.
On April 28, 2017, WellCare Health Plans (WCG) completed the acquisition of Universal American Corp. This deal added 119,000 Medicare Advantage members from several major markets
Zoetis (ZTS) expects to generate savings of over $300 million in 2017 through its operational efficiency program.
In 1Q17, Zoetis (ZTS) managed to earn $615 million as revenues from international markets, which represents a YoY growth of around 8%.
In 1Q17, Zoetis’s (ZTS) dermatology portfolio reported revenues of ~$57 million, driven by the steady adoption of Cytopoint and Apoquel.
In 1Q17, Zoetis’s key livestock brands Excede anti-infective, Excenel RTU, Fostera, and Bovi-Shield witnessed label expansions.
In 1Q17, Zoetis’s (ZTS) Companion Animal Health segment saw revenues of ~$517 million, which represents a YoY operational growth of around 12%.
Zoetis (ZTS) has adopted a targeted R&D strategy that has resulted in multiple new product launches.
Zoetis (ZTS) expects the animal health market to grow YoY in the range of 5%–6% in 2017.
Dentsply Sirona (XRAY) released its 1Q17 results on May 9, 2017. Let’s take a look at Wall Street analysts’ recommendations and target prices for XRAY over the next year.
Dentsply Sirona (XRAY) expects its 2017 constant currency revenue to witness a YoY (year-over-year) rise of 4%–6%, in line with its previous guidance.
Dentsply Sirona is the largest dental equipment and solutions manufacturer in the United States. Digital dentistry is a megatrend in the market.
Dentsply Sirona (XRAY) reported ~$900 million of revenues worldwide in 1Q17. Of that, ~$511 million was generated by the Dental and Healthcare Consumables segment, which contributed ~56.8% to Dentsply Sirona’s…
Dentsply Sirona (XRAY) reported ~$900 million of revenues worldwide in 1Q17. Of that, ~$389 million was generated through Dentsply Sirona’s Technology segment, which contributed ~43.2% to Dentsply Sirona’s total revenues. On…